[Seoul=Newsis] As digital therapeutics are expected to grow rapidly each year, there is also a forecast that digital therapeutics related to diabetes and obesity, which have recently gained significant attention, will increase in the future.

According to a report on global health industry trends from the Korea Health Industry Development Institute on the 27th, the digital therapeutics market is expected to continue growing from now until 2028-2032.

Digital therapeutics are evidence-based (proven effective through scientific research and clinical evidence) treatments that use software apps to prevent, manage, or treat chronic diseases and disabilities. Unlike traditional forms of treatment, digital therapeutics feature the use of digital platforms, including mobile apps, software, and wearable devices, to provide personalized interactive health solutions.

Global research group OpenPR predicted that the digital therapeutics market will grow at a compound annual growth rate (CAGR) of 28.6% from 2023 to 2031, with the market size expected to reach $43.2 billion (approximately KRW 59.7 trillion) by 2031. Similarly, GMI predicted that the digital therapeutics market would grow at a CAGR of 31.5% by 2032, reaching a market size of $104 billion (approximately KRW 143.8 trillion) by that year.

Digital therapeutics are categorized by disease into areas such as diabetes, obesity, cardiovascular diseases, central nervous system (CNS) disorders, gastrointestinal disorders, respiratory diseases, and smoking cessation. Recently, diabetes and obesity, which are experiencing a global shortage of pharmaceutical supplies, are also expected to grow in the digital therapeutics sector.

In fact, according to data from the global market research and consulting firm Precedence Research, diabetes accounted for the largest market share (28.8%) of digital therapeutics as of last year. With the number of obesity patients expected to increase rapidly, new digital therapeutics for diabetes and obesity are anticipated to be launched.

For example, Noom, which has received approval as a digital therapeutic, offers a weight loss program for prediabetes and overweight patients. The U.S.-based digital therapeutics company Virta Health provides solutions for treating type 2 diabetes without medication or surgery and also shows improvement in areas such as blood pressure, inflammation, liver function, and obesity.

A representative from the Korea Health Industry Development Institute stated, "Due to the continuous advancement of digital health technology and the growing demand for personalized healthcare solutions, the digital therapeutics market will continue to expand." They added, "The digital therapeutics market is experiencing a surge in funding and investment, and this influx of capital demonstrates the potential of digital therapeutics to enhance the efficiency of healthcare services worldwide."

◎공감언론 뉴시스 hjhee@newsis.com

source : https://newsis.com/view/NISX20240726_0002826703

This article is a translation of a Korean original into English.